🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 Call for Papers! The 4 ESTRO journals are uniting for a landmark issue on reirradiation—a cutting-edge approach offering new hope to patients with recurrent cancers. Submit your research & help shape the future of cancer care! 🔗 thegreenjournal.com/content/Reirra… #Reirradiation #RadOnc

Submit your papers for our special issue on reirradiation!!! Cc ESTRO Phiro Tweets Tipsro Tweets

🌍 Society Matters — a new section in the Green Journal! Exploring how radiation oncology intersects with climate, equity, policy & more. 📖 Read the first editorial: sciencedirect.com/science/articl… 💬 What should we cover next? #RadiationOncology #SocietyMatters #ESTRO #Sustainability

📌✅ Sustainable radiation oncology in a world with grand environmental and societal challenges: Society Matters – A new section in the Green Journal 🟢📄 sciencedirect.com/science/articl… Kari Tanderup Birgitte Offersen Rob Coppes Pierre Blanchard, MD ESTRO Radiotherapy & Oncology OncoAlert

🤖 New in the Green Journal: Most radiation oncology patients support AI/ML in their care — but they want transparency, human connection, and equity. 📄 Read the study: sciencedirect.com/science/articl… #RadiationOncology #AIinHealthcare #GreenJournal #SocietyMatters #ESTRO

We would not exist without our reviewers. Many thanks for their time and commitment to our journal and community. #radonc #ESTRO25 cc ESTRO

📢 Don’t miss the Green Journal–Lancet Oncology joint plenary at #ESTRO2025! 🗓 Sun May 4 | ⏰ 11:40–12:45 📍 Plenary Hall Top clinical trials in GI & SBRT from 🇬🇧 🇳🇱 🇨🇳 — including PLATO ACT 4, STAR-TREC, PRIME-RT & more. #Radiotherapy #Oncology #GreenJournal

⁦GETUG⁩ V04 randomized study on Gem/Cis chemoradiation for #bladdercancer presented by ⁦Morgan Michalet⁩. Surprising lower survival (NS but small cohort) that may be a cause of concern. Related to higher metastases in Gem/Cis group. #ESTRO25

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt. Compared to 40Gy/15, 26Gy/5: 1. Non inf for IBR (even superior?) 2. Similar recurrence free interval, breast cancer interval, OS 3. No diff in PRO or toxicity Clearly 26/5 SOC for

🚨Birgitte Offersen reports on SKAGEN-1 trial of hypofractionation (40/15 vs 50/25) #ESTRO25 1. Safe: similar lymphedema 2. Effective: similar locoregional and distance recurrence, OS BUT increased #breastcancer mortality, across subgroups & w/o explanation. Discussions to follow…

🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)

Words of wisdom from Michael Baumann, MD on the future of radiation oncology, recipient of the 2025 Jens Overgaard award. Well deserved! #ESTRO25

SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25

Reassuring toxicity data from PCS IX trial after hypofractionated (5*5 Gy) pelvic & prostate #radiotherapy priori to #brachytherapy boost for #prostatecancer. #ESTRO25

Bounce (defined as an increase > 0.2 ng/mL) following ultra hypofrac #radiotherapy, is frequent (36%) & associated with improved prognosis. Data from HYPO RT PC at #ESTRO25 Possible bias (bounces by definition have a decrease in PSA after the rise) role of 3y landmark analysis

Nivolumab concurrent and adjuvant with TMT may improve bladder PFS and OS in MIBC receiving bladder preservation protocol. Small randomized phase II trial presented at #ESTRO25 Waiting for GETUG BLADDER SPARING with atezo and larger phase III trials. Paul Sargos

Caution when abandoning ENI in HNSCC. Very sensible and prudent message by Julian Biau MD, PhD. Excellent debate. #ESTRO25

STORM-PEACE V trial reported by Thomas Zilli #ESTRO25 Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each) Improves Biochemical PFS Locoregional PFS MFS ADT free survival Tox NS ENI clear SOC Online The Lancet Oncology Cc Piet Ost

🚀 Thrilled to announce 3 new clinical trials in Radiotherapy & Oncology in partnership with The Lancet Oncology Lancet Oncology): ✨ ESO-SPARE 🔍 DBCG IMN2 post-hoc 📊 FAST-Forward nodal sub-study More details coming soon! 👀 #ESTRO2025 #GreenJournal

The field of #HeadNeckCancer just got more interesting! #ASCO2025 #Plenary NIVO-POSTOP study was an important IIS for high risk HNSCC Positive DFS @ 3y But signal is primarily locoregional control! Stark contrast to KN689 Kudos to GORTEC Pierre Blanchard, MD Thoughts??